AlzChem Group (ACT) Q4 2024 earnings summary

Executive summary

• Achieved record sales of EUR 554 million in 2024, up 3% year-over-year, with Specialty Chemicals driving growth and accounting for 63% of total sales and nearly 90% of earnings contribution.

• EBITDA reached a record EUR 105.3 million, up 30% year-over-year, with an EBITDA margin of 19% (up from 15.1%).

• Net income rose to EUR 54.2 million, a 56% increase, supporting a proposed dividend of EUR 1.80 per share, up 50%.

• Major investment project of approximately EUR 140 million underway, with site selection in the USA progressing and construction activities starting.

• Included in the SDAX index and received a platinum EcoVadis ESG rating, placing in the top 1% of companies.

Financial highlights

• Group sales increased by 3% to EUR 554 million, the highest in company history.

• EBITDA rose by EUR 24 million to EUR 105.3 million, a 30% increase year-over-year.

• Net financial position improved from EUR 46 million net debt to EUR 12.9 million net financial asset.

• Equity increased to EUR 207 million, with an equity ratio of 43%.

• Operating cash flow surged 45% to EUR 105 million.

Outlook and guidance

• 2025 sales expected to reach EUR 580 million (+5%), with EBITDA forecast at EUR 113 million (+7%).

• Growth to be driven by volume increases in Specialty Chemicals (Creapure, Creamino, nitroguanidine), with slight decline in Basics and Intermediates.

• Custom manufacturing volumes and sales anticipated to recover as European chemical industry stabilizes.

• CapEx for 2025 projected at around EUR 100 million, before EU subsidies.

• Outlook assumes stable global economy, high electricity prices, and no major geopolitical disruptions.